PE20141669A1 - Moduladores selectivos del receptor androgeno - Google Patents

Moduladores selectivos del receptor androgeno

Info

Publication number
PE20141669A1
PE20141669A1 PE2014000521A PE2014000521A PE20141669A1 PE 20141669 A1 PE20141669 A1 PE 20141669A1 PE 2014000521 A PE2014000521 A PE 2014000521A PE 2014000521 A PE2014000521 A PE 2014000521A PE 20141669 A1 PE20141669 A1 PE 20141669A1
Authority
PE
Peru
Prior art keywords
methyl
selective androgen
cyclopentil
benzonitrile
chloro
Prior art date
Application number
PE2014000521A
Other languages
English (en)
Spanish (es)
Inventor
Prabhakar Kondaji Jadhav
Ashraf Saeed
Jonathan Edward Green
Venkatesh Krishnan
Donald Paul Matthews
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141669(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20141669A1 publication Critical patent/PE20141669A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2014000521A 2011-10-13 2012-10-05 Moduladores selectivos del receptor androgeno PE20141669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161546711P 2011-10-13 2011-10-13

Publications (1)

Publication Number Publication Date
PE20141669A1 true PE20141669A1 (es) 2014-11-08

Family

ID=47046879

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000521A PE20141669A1 (es) 2011-10-13 2012-10-05 Moduladores selectivos del receptor androgeno

Country Status (28)

Country Link
US (1) US8658693B2 (enExample)
EP (1) EP2766350B1 (enExample)
JP (1) JP6002228B2 (enExample)
KR (1) KR20140067102A (enExample)
CN (1) CN103842348B (enExample)
AP (1) AP2014007548A0 (enExample)
AR (1) AR088082A1 (enExample)
AU (1) AU2012321113B2 (enExample)
BR (1) BR112014008668A2 (enExample)
CA (1) CA2847889A1 (enExample)
CL (1) CL2014000895A1 (enExample)
CO (1) CO6910195A2 (enExample)
CR (1) CR20140156A (enExample)
DO (1) DOP2014000075A (enExample)
EA (1) EA201490519A1 (enExample)
EC (1) ECSP14013305A (enExample)
ES (1) ES2626820T3 (enExample)
GT (1) GT201400067A (enExample)
IL (1) IL231440A0 (enExample)
MX (1) MX2014004558A (enExample)
PE (1) PE20141669A1 (enExample)
PH (1) PH12014500808A1 (enExample)
PL (1) PL2766350T3 (enExample)
PT (1) PT2766350T (enExample)
SG (1) SG11201401794YA (enExample)
TN (1) TN2014000136A1 (enExample)
TW (1) TWI449686B (enExample)
WO (1) WO2013055577A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
US10093660B2 (en) 2013-12-04 2018-10-09 Evotec Internatonal Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
JP6479854B2 (ja) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングEvotec International GmbH 医薬組成物のためのスルホキシイミン置換キナゾリン
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
PL3507289T3 (pl) 2016-09-02 2021-01-25 Suven Life Sciences Limited Dodatnie allosteryczne modulatory receptora muskarynowego m1
EP3684761A1 (en) 2017-09-18 2020-07-29 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
JP7778095B2 (ja) * 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
WO2025104624A1 (en) * 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594405A (en) * 1968-05-17 1971-07-20 Du Pont Substituted pyranyl anilines as plant growth modifiers
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
DE602006003432D1 (de) * 2005-05-13 2008-12-11 Lilly Co Eli Latoren des androgenrezeptors
BRPI0619208A2 (pt) * 2005-11-30 2011-09-20 Astellas Pharma Inc derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
US8190467B2 (en) * 2007-10-19 2012-05-29 Michelle Letendre-Hedlund Methods of identifying environmentally friendly businesses or individuals
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos

Also Published As

Publication number Publication date
SG11201401794YA (en) 2014-09-26
CN103842348B (zh) 2015-08-19
GT201400067A (es) 2015-02-27
AR088082A1 (es) 2014-05-07
US20130217762A1 (en) 2013-08-22
PT2766350T (pt) 2017-05-22
AU2012321113A1 (en) 2014-03-27
EP2766350B1 (en) 2017-04-05
CA2847889A1 (en) 2013-04-18
ECSP14013305A (es) 2014-05-31
US8658693B2 (en) 2014-02-25
JP6002228B2 (ja) 2016-10-05
DOP2014000075A (es) 2014-06-01
TN2014000136A1 (en) 2015-07-01
CO6910195A2 (es) 2014-03-31
EA201490519A1 (ru) 2014-09-30
PL2766350T3 (pl) 2017-08-31
EP2766350A1 (en) 2014-08-20
ES2626820T3 (es) 2017-07-26
JP2014530818A (ja) 2014-11-20
KR20140067102A (ko) 2014-06-03
CN103842348A (zh) 2014-06-04
AP2014007548A0 (en) 2014-03-31
CR20140156A (es) 2014-05-16
BR112014008668A2 (pt) 2017-04-25
PH12014500808A1 (en) 2019-07-03
AU2012321113B2 (en) 2015-07-09
MX2014004558A (es) 2014-08-01
WO2013055577A1 (en) 2013-04-18
TW201329026A (zh) 2013-07-16
CL2014000895A1 (es) 2014-08-22
TWI449686B (zh) 2014-08-21
IL231440A0 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
EA201170676A1 (ru) Агонисты рецептора меланокортина
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2022010305A2 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas
HN2012001351A (es) Derivados de 3- hidroxi-5-arilisotiazol novedosos
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
DOP2013000181A (es) Moduladores del receptor de glucagon
EA201190021A1 (ru) Модуляторы toll-подобных рецепторов
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
PE20160996A1 (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
ECSP11011398A (es) Inhibidores de beta-secretasa
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EA201291476A1 (ru) Комбинации, содержащие атипичные антипсихотические средства и агонисты taar1
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
CL2014000895A1 (es) Compuestos derivados de {2-cloro-4-[hidroxi(cicloalquil/heterociclil)]amino]fenil}acetonitrilo, moduladores selectivos del receptor androgeno; composicion farmaceutica; composicion farmceutica que comprende una forma cristalina; y su uso en el tratamiento de la atrofia muscular
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina

Legal Events

Date Code Title Description
FD Application declared void or lapsed